A novel bispecific diabody targeting both vascular endothelial growth factor receptor 2 and epidermal growth factor receptor for enhanced antitumor activity.

Xu, Menghuai; Jin, Haizhen; Chen, Zhiguo; Xie, Wei; Wang, Youfu; Wang, Yang; Wang, Min; Zhang, Juan; Acheampong, Desmond Omane

Xu, Menghuai; Jin, Haizhen; Chen, Zhiguo; Xie, Wei; Wang, Youfu; Wang, Yang; Wang, Min; Zhang, Juan; Acheampong, Desmond Omane.

Afiliação

Xu M; State Key Laboratory of Natural Medicines (China Pharmaceutical University), School of Life Science & Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Jin H; State Key Laboratory of Natural Medicines (China Pharmaceutical University), School of Life Science & Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Chen Z; State Key Laboratory of Natural Medicines (China Pharmaceutical University), School of Life Science & Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Xie W; State Key Laboratory of Natural Medicines (China Pharmaceutical University), School of Life Science & Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Wang Y; State Key Laboratory of Natural Medicines (China Pharmaceutical University), School of Life Science & Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Wang Y; State Key Laboratory of Natural Medicines (China Pharmaceutical University), School of Life Science & Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Wang M; State Key Laboratory of Natural Medicines (China Pharmaceutical University), School of Life Science & Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Zhang J; State Key Laboratory of Natural Medicines (China Pharmaceutical University), School of Life Science & Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Acheampong DO; State Key Laboratory of Natural Medicines (China Pharmaceutical University), School of Life Science & Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.

Biotechnol Prog ; 32(2): 294-302, 2016 03.

Article em En | MEDLINE | ID: mdl-26785424

Assuntos

Anticorpos Biespecíficos/metabolismo; Antineoplásicos/farmacologia; Receptores ErbB/antagonistas & inibidores; Receptor 2 de Fatores de Crescimento do Endotélio Vascular/antagonistas & inibidores; Animais; Anticorpos Biespecíficos/biossíntese; Anticorpos Biespecíficos/química; Antineoplásicos/química; Antineoplásicos/isolamento & purificação; Apoptose/efeitos dos fármacos; Linhagem Celular Tumoral; Movimento Celular/efeitos dos fármacos; Proliferação de Células/efeitos dos fármacos; Galinhas; Relação Dose-Resposta a Droga; Ensaios de Seleção de Medicamentos Antitumorais; Receptores ErbB/metabolismo; Humanos; Neoplasias Experimentais/tratamento farmacológico; Neoplasias Experimentais/patologia; Relação Estrutura-Atividade; Receptor 2 de Fatores de Crescimento do Endotélio Vascular/metabolismo

Palavras-chave

antiangiogenesis; antitumor; bispecific diabody (bDAb); epidermal growth factor receptor (EGFR); single-chain fragment (scFv); vascular endothelial growth factor receptor 2 (VEGFR2)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Biespecíficos / Receptor 2 de Fatores de Crescimento do Endotélio Vascular / Receptores ErbB / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Biotechnol Prog Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google